DeğerQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSatış/genel/idari giderler18.12 M19.3 M18.92 M16.93 M18.4 M17.18 M71.43 MAraştırma ve geliştirme82.16 M72.48 M69.89 M58.9 M83.53 M68.57 M280.9 MFaaliyet karı-64.59 M-148.42 M-229.32 M-132.06 M-154.76 M-130.25 M-646.39 MFaaliyet Dışı Gelir, Toplam27.98 M13.54 M22.07 M26.24 M24.77 M8.16 M81.22 MFaiz gideri (aktifleştirilmiş faizler düşüldükten sonra)—————553 K—Faaliyet Dışı Gelir (Faiz Giderleri Hariç)00000-553 K-553 KOlağandışı gelirler/giderler27.98 M13.54 M22.07 M26.24 M24.77 M8.16 M81.22 MVergi öncesi kar-36.61 M-134.89 M-207.26 M-105.82 M-130 M-122.09 M-565.17 MKazançlardaki özsermayeler———————Vergiler700 K1.11 M1.29 M619 K614 K839 K3.36 MKontrol gücü olmayan/azınlık payı———————Vergi sonrası diğer gelirler/giderler15.15 M-2.25 M7.33 M10.14 M8.31 M-8.8 M16.98 MDurdurulan faaliyetler öncesi net kar-37.31 M-136 M-208.55 M-106.44 M-130.61 M-122.93 M-568.53 MDurdurulan faaliyetler———————Net kar-37.31 M-136 M-208.55 M-106.44 M-130.61 M-122.93 M-568.53 MSeyreltme ayarlaması———————İmtiyazlı temettüler———————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar-37.31 M-136 M-208.55 M-106.44 M-130.61 M-122.93 M-568.53 MTemel hisse başına kazanç (Temel EPS)-0.41-1.58-2.4-1.17-1.32-1.28-6.17Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)-0.41-1.58-2.4-1.17-1.32-1.28-6.17Dolaşımdaki ortalama adi hisse senedi sayısı84.36 M85.94 M87.07 M91.31 M89.93 M96.05 M—Dolaşımdaki seyreltilmiş hisse senedi sayısı84.36 M85.94 M87.07 M91.31 M89.93 M96.05 M—FAVÖK-59.75 M-143.69 M-224.68 M-127.63 M-149.1 M-125.93 M-627.33 MFVÖK-64.59 M-148.42 M-229.32 M-132.06 M-154.76 M-130.25 M-646.39 MGelir maliyeti———————Satılan malların diğer maliyeti———————Amortisman ve itfa (nakit akışı)4.84 M4.74 M4.65 M4.43 M5.66 M4.32 M19.06 M
CRISPR Therapeutics AG - Common Shares
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.